Will The Dark Tunnel For Korean Biopharmas End In 2023?

Eyes On Lung Cancer, Alzheimer’s Segment

 
• By Jung Won Shin
  
Man walk through crystal corridor
Korean Firms See Decline In Financing, Licensing Deals In 2022 • Source: Shutterstock

More from Business

More from Scrip